Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5α-reductase inhibitor, in normal subjects treated with single or multiple doses-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5α-reductase inhibitor, in normal subjects treated with single or multiple doses

Published:2002-09 Issue:3 Volume:54 Page:283-294
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Fujita Tomoe,Matsumoto Yoshiaki,Kimura Toshimi,Yokota Shinichi,Sawada Mika,Majima Masataka,Ohtani Yoshio,Kumagai Yuji

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2125.2002.01656.x/fullpdf

Reference28 articles.

1. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia;Claus;J Urol,1997

2. Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia;Colombel;Br J Urol,1998

3. Apoptotic versus proliferative activities in human benign prostatic hyperplasia;Kyprianou;Hum Pathol,1996

4. The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells;Grant;J Clin Endocrinol Metab,1998

5. Steroid hormones and the pathogenesis of benign prostatic hyperplasia;Griffiths;Eur Urol,1991

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Self-[3+2] annulation reaction of pyridinium salts: synthesis of N-indolizine-substituted pyridine-2(1H)-ones;New Journal of Chemistry;2022

2. Palladium-catalyzed direct and regioselective C–H acyloxylation of indolizines;Organic & Biomolecular Chemistry;2015

3. Multisubstituted N-fused heterocycles via transition metal-catalyzed cycloisomerization protocols;Tetrahedron;2008-07

4. Low Temperature Organocopper-Mediated Two-Component Cross Coupling/Cycloisomerization Approach Toward N-Fused Heterocycles;Organic Letters;2008-05-08

5. Benign Prostatic Hyperplasia;Wiley Handbook of Current and Emerging Drug Therapies;2006-10-13